Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
Purpose: A systematic review and meta-analysis was conducted to combine the data available from clinical trials and evaluate the clinical efficacy and safety of tirzepatide in people with type 2 diabetes (T2D).Methods: We systematically searched the MEDLINE, Embase, Cochrane Library, and clinical tr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1016639/full |
| _version_ | 1811205664863682560 |
|---|---|
| author | Yan Tang Lin Zhang Yuping Zeng Xia Wang Mei Zhang |
| author_facet | Yan Tang Lin Zhang Yuping Zeng Xia Wang Mei Zhang |
| author_sort | Yan Tang |
| collection | DOAJ |
| description | Purpose: A systematic review and meta-analysis was conducted to combine the data available from clinical trials and evaluate the clinical efficacy and safety of tirzepatide in people with type 2 diabetes (T2D).Methods: We systematically searched the MEDLINE, Embase, Cochrane Library, and clinical trials registries (https://clinicaltrials.gov) up to 25 March 2022 for randomized controlled trials (RCTs) that compared tirzepatide with placebo or active hypoglycemic drugs in subjects with T2D. Heterogeneity was judged by the I2 value and Cochran’s Q test. The randomized effects model was adopted to calculate risk ratios and weighted mean differences (WMDs). The primary outcome was the change from baseline in HbA1c levels. Secondary efficacy endpoints were fasting serum glucose (FSG), change of body weight, blood pressure, fasting lipid profiles, and safety indexes.Results: Six trials comprising 6,579 subjects (4,410 in the tirzepatide group and 2,054 in the control group) fulfilled the pre-specified criteria and were included in the study. Tirzepatide treatment resulted in reducing HbA1c (WMD: -1.07%; 95% confidence intervals [CIs]: −1.44, −0.56), FSG (WMD, −21.50 mg/dl; 95% CI: −34.44, −8.56), body weight (WMD: −7.99 kg; 95% CI −11.36, −4.62), and blood pressure and ameliorated fasting lipid profiles, without increasing hypoglycemia, either as monotherapy or an add-on therapy. Tirzepatide increased the risk of gastrointestinal adverse events mainly in add-on therapy but not in terms of pancreatitis or cholelithiasis. Furthermore, tirzepatide presented a dose–response effect on the reduction in HbA1c and body weight and increase in nausea and vomiting.Conclusion: In patients with type 2 diabetes, tirzepatide shows superior blood glucose control and weight loss performance, without an increased risk of hypoglycemia.Systematic Review Registration: (https://www.crd.york.ac.uk/PROSPERO), identifier (CRD42022319442). |
| first_indexed | 2024-04-12T03:35:54Z |
| format | Article |
| id | doaj.art-c49a035f9cb9487483a954069817798c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T03:35:54Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c49a035f9cb9487483a954069817798c2022-12-22T03:49:26ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.10166391016639Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysisYan Tang0Lin Zhang1Yuping Zeng2Xia Wang3Mei Zhang4Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, ChinaGeneral Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, ChinaPurpose: A systematic review and meta-analysis was conducted to combine the data available from clinical trials and evaluate the clinical efficacy and safety of tirzepatide in people with type 2 diabetes (T2D).Methods: We systematically searched the MEDLINE, Embase, Cochrane Library, and clinical trials registries (https://clinicaltrials.gov) up to 25 March 2022 for randomized controlled trials (RCTs) that compared tirzepatide with placebo or active hypoglycemic drugs in subjects with T2D. Heterogeneity was judged by the I2 value and Cochran’s Q test. The randomized effects model was adopted to calculate risk ratios and weighted mean differences (WMDs). The primary outcome was the change from baseline in HbA1c levels. Secondary efficacy endpoints were fasting serum glucose (FSG), change of body weight, blood pressure, fasting lipid profiles, and safety indexes.Results: Six trials comprising 6,579 subjects (4,410 in the tirzepatide group and 2,054 in the control group) fulfilled the pre-specified criteria and were included in the study. Tirzepatide treatment resulted in reducing HbA1c (WMD: -1.07%; 95% confidence intervals [CIs]: −1.44, −0.56), FSG (WMD, −21.50 mg/dl; 95% CI: −34.44, −8.56), body weight (WMD: −7.99 kg; 95% CI −11.36, −4.62), and blood pressure and ameliorated fasting lipid profiles, without increasing hypoglycemia, either as monotherapy or an add-on therapy. Tirzepatide increased the risk of gastrointestinal adverse events mainly in add-on therapy but not in terms of pancreatitis or cholelithiasis. Furthermore, tirzepatide presented a dose–response effect on the reduction in HbA1c and body weight and increase in nausea and vomiting.Conclusion: In patients with type 2 diabetes, tirzepatide shows superior blood glucose control and weight loss performance, without an increased risk of hypoglycemia.Systematic Review Registration: (https://www.crd.york.ac.uk/PROSPERO), identifier (CRD42022319442).https://www.frontiersin.org/articles/10.3389/fphar.2022.1016639/fulltype 2 diabetestirzepatideHbA1cweight losshypoglycemiameta-analysis |
| spellingShingle | Yan Tang Lin Zhang Yuping Zeng Xia Wang Mei Zhang Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis Frontiers in Pharmacology type 2 diabetes tirzepatide HbA1c weight loss hypoglycemia meta-analysis |
| title | Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis |
| title_full | Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis |
| title_short | Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis |
| title_sort | efficacy and safety of tirzepatide in patients with type 2 diabetes a systematic review and meta analysis |
| topic | type 2 diabetes tirzepatide HbA1c weight loss hypoglycemia meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1016639/full |
| work_keys_str_mv | AT yantang efficacyandsafetyoftirzepatideinpatientswithtype2diabetesasystematicreviewandmetaanalysis AT linzhang efficacyandsafetyoftirzepatideinpatientswithtype2diabetesasystematicreviewandmetaanalysis AT yupingzeng efficacyandsafetyoftirzepatideinpatientswithtype2diabetesasystematicreviewandmetaanalysis AT xiawang efficacyandsafetyoftirzepatideinpatientswithtype2diabetesasystematicreviewandmetaanalysis AT meizhang efficacyandsafetyoftirzepatideinpatientswithtype2diabetesasystematicreviewandmetaanalysis |